Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2025

Conditions
Pancretic CancerDiabete Mellitus
Interventions
DRUG

Metformin or insulin treatment

"1. For patients with new-onset diabetes Fasting blood glucose 7-10 mmol/L, metformin 2 g/day, BID, PO; Fasting blood glucose 10-14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 12 U before breakfast, 8 U; Fasting blood glucose \> 14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 16 U before breakfast, 10 U; Adjusting insulin dosage according to the monitor of fasting blood glucose.~2. For patients with history of diabetes Adjusting metformin or insulin dosage according to the monitor of fasting blood glucose."

Trial Locations (1)

200032

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER